Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.
Nilanjan Ghosh, MD, PhD, director, Lymphoma Program, physician, Levine Cancer Institute, discusses the need to develop novel therapies in diffuse large B-cell lymphoma (DLBCL).
Up to 70% of patients with DLBCL, as well as other aggressive large B-cell lymphomas, may derive a long-term remission or cure from standard frontline chemoimmunotherapy regimens, says Ghosh.
Autologous stem cell transplant (ASCT) should be considered for chemotherapy-sensitive patients who relapse, he adds.
However, some patients who relapse are ineligible for ASCT due to poor prognostic features or comorbidities, says Ghosh. As such, novel therapies to treat patients who are chemotherapy refractory and ineligible for transplant are needed.
CAR T-cell therapies including lisocabtagene maraleucel (liso-cel) may have utility in this space, concludes Ghosh.